CN1513486A - Liver-care composition and its prepn. method - Google Patents
Liver-care composition and its prepn. method Download PDFInfo
- Publication number
- CN1513486A CN1513486A CNA021608997A CN02160899A CN1513486A CN 1513486 A CN1513486 A CN 1513486A CN A021608997 A CNA021608997 A CN A021608997A CN 02160899 A CN02160899 A CN 02160899A CN 1513486 A CN1513486 A CN 1513486A
- Authority
- CN
- China
- Prior art keywords
- liver
- protects
- compositions
- solid
- described preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A liver-protecting composition is prepared through crashing capillary artemisia and capejasmine fruit, decocting, soaking rhubarb in alcohol, mixing both together to generate the first solid phase and the first liquid phase, concentrating the first liquid phase, adding alcohol, deposition to generate the second solid phase and the second liquid phase, and drying the second solid phase.
Description
Technical field
The invention relates to a kind of middle medicinal herbs composition and method of making the same, refer to that especially a kind for the treatment of hepatitis that is applicable to protects the liver composition and method of making the same.
Background technology
Chronic hepatopathy (chronic hepatitis, liver cirrhosis and hepatocarcinoma) is the natural enemy of human health, and hepatopathy can be divided into viral liver disease, alcoholic liver disease, medicine or poisonous substance hepatopathy and pathobolism hepatopathy by its cause of disease.It is the carrier of chronic hepatitis b that the whole world has 300,015,000 populations at present approximately, and 2,700,000 people are the patient of chronic hepatitis c.In Taiwan, hepatopathy is also quite rampant, and the former rate of hepatitis B band is about 15～20%, and the full court gulf also has 2-4% population to be subjected to hepatitis C virus to infect, and the market of therefore developing hepatitis medicament is very big.
Present western medical treatment hepatopathy, employed hepatic or antiviral drugs or immunomodulator etc., though certain curative effect is arranged, side effect is big and expense is expensive.As treat interferon that hepatitis B uses and Lamivudine etc., interferon allowed to use the medication of treatment chronic hepatitis b in 1992 for U.S. FDA, not only side effect is very big, to hepatitis B, also only there is 20% patient to respond, and Lamivudine was used for treating hepatitis B in 1998 by FDA and also has only the patient of 17-33% to respond, and Lamivudine causes the sudden change of hepatitis virus B easily, so that had reduced the effect of treatment.
And hepatopathy is in the treatment of the traditional Chinese medical science, and tradition prescription or folk prescription among the people are adopted by big portion, but often low because of cure rate, repeatability is poor (can't effectively be grasped as processing procedure, no certain quality management and control etc.), and often need determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs and delay treatment, so Chinese medicine often there are bottleneck and blind spot in the treatment of hepatopathy.
The present invention is through further investigation; certainly the certain contribution of Chinese herbal medicine on the treatment hepatopathy; the compositions useful of treatment hepatopathy and the extraction process technique of effective therapeutic component also are provided; for because of medicine or the caused liver inflammation of other chemical (as alcoholic liver disease) phenomenon; have the liver protective effect, be worth the reference for the treatment of as chronic hepatitis patient clinically.
In the streets use Chinese medicine how all medical materials to be drunk in the decocting mode of boiling, but the method often can't obtain the active component of q.s, and the active component of some drugs meeting loss of activity after high temperature decocts, can't bring into play drug effect.Disclosed many hepatic processing procedures among patent documentation CN1194840, CN 1110151, CN 1136941, the CN 119540, but its medical material is of a great variety, and, can't addresses the above problem with conventional art production.Therefore, the people is also arranged with the active substance in the natural goods extraction organic solvent extraction Chinese medicine commonly used, as patent documentation JP6322116, JP 58183623, US 5529778, US 5145955 etc., but employed organic solvent such as methanol, acetone, chloroform etc., quite big to human toxicity, if thoroughly do not remove, and be not suitable for human body.Therefore, need develop a kind of new preparation method of composition that protects the liver in the market, the effective ingredient that its product comprised is higher than the product of traditional mode of production processing procedure, keeps more active substances, better efficacy; And do not use deleterious organic solvent in the process, increase the safety of medicine.
Summary of the invention
Main purpose of the present invention is a kind of compositions that protects the liver to be provided, the liver defencive function can be provided, and then as the medicine of chronic hepatitis patient.
Another object of the present invention is that a kind of manufacture method that protects the liver compositions is being provided, the effective active substance in the extracts composition, and do not contain poisonous organic solvent.
For reaching above-mentioned purpose, a kind of preparation of compositions method that protects the liver provided by the invention comprises the following steps:
(a) with Herba Artemisiae Scopariae and Fructus Gardeniae crushing and water-adding and heating;
(b) with this water collection liquid, add an alcohol-pickled liquid that contains Radix Et Rhizoma Rhei and mix, form one first solid phase and one first liquid phase;
(c) get this first liquid phase layer and concentrating, make this first liquid phase layer form concentrated solution; And
(d) in this concentrated solution, add ethanol and make it produce precipitation, form second solid phase and second liquid phase, get this second solid-phase layer, and with this second solid matter drying.
The described preparation of compositions method that protects the liver, it more is contained in and adds the alcohol-pickled liquid that contains Fructus Schisandrae Chinensis in the step (b).
The described preparation of compositions method that protects the liver, wherein the concentration step of this step (c) is to be the concentrated solution of 1-30% percentage by weight with this water collection liquid simmer down to solid holdup.
The described preparation of compositions method that protects the liver, wherein the ethanol final weight percent concentration of this step (d) is that 71%-90% is heavy.
The described preparation of compositions method that protects the liver, wherein the ethanol final weight percent concentration of this step (d) is that 30%-70% is heavy.
The described preparation of compositions method that protects the liver, it more is contained in, and adding ethanol to ethanol final weight percent concentration reaches 75% to 90% weight in this second liquid phase layer, to form the 3rd solid-phase layer and the 3rd liquid phase layer, get the 3rd solid-phase layer, and with the 3rd solid matter drying.
The described preparation of compositions method that protects the liver, wherein this Herba Artemisiae Scopariae is a Herba Artemisiae Scopariae, Herba Artemisiae Annuae, capillary wormwood, or its generic plant.
The described preparation of compositions method that protects the liver, wherein this Fructus Gardeniae is a SHANZHIZI, Fructus Gardeniae grandiflorae, or its generic plant.
The described preparation of compositions method that protects the liver, wherein this Radix Et Rhizoma Rhei is a Radix Et Rhizoma Rhei, water root Radix Et Rhizoma Rhei, or its generic plant.
The described preparation of compositions method that protects the liver, wherein this step (a) more comprises the step of boiling with stirring.
The described preparation of compositions method that protects the liver, wherein the cooling step of this step (a) is to be cooled to 10-80 ℃.
The described preparation of compositions method that protects the liver, wherein this step (b) is to mix down in 10-80 ℃.
The described preparation of compositions method that protects the liver, wherein the drying means of this step (d) is with lyophilization or spray drying or thermopnore drying.
The described preparation of compositions method that protects the liver, wherein the part by weight of this Herba Artemisiae Scopariae and Fructus Gardeniae and Radix Et Rhizoma Rhei is 4-8: 3-6: 0.5-2.5.
The described preparation of compositions method that protects the liver, it more comprises the end product drying and crushing, pelletize and capsule charge.
Be realization the object of the invention, a kind of compositions that protects the liver provided by the invention, it is to make in the following manner:
(a) with Herba Artemisiae Scopariae and Fructus Gardeniae crushing and water-adding and heating;
(b) with this water collection liquid, add an alcohol-pickled liquid that contains Radix Et Rhizoma Rhei and mix, form first solid phase and first liquid phase;
(c) get this first liquid phase layer and concentrating, make this first liquid phase layer form concentrated solution; And
(d) in this concentrated solution, add ethanol and make it produce precipitation, form second solid phase and second liquid phase, get this second solid-phase layer, and with this second solid matter drying.
The described compositions that protects the liver, it more is contained in and adds the alcohol-pickled liquid that contains Fructus Schisandrae Chinensis in the step (b).
The described compositions that protects the liver, wherein the concentration step of this step (c) is to be the concentrated solution of 1-30% percentage by weight with this water collection liquid simmer down to solid holdup.
The described compositions that protects the liver, wherein the ethanol final weight percent concentration of this step (d) is that 71%-90% is heavy.
The described compositions that protects the liver, wherein the ethanol final weight percent concentration of this step (d) is that 30%-70% is heavy.
The described compositions that protects the liver, it more is contained in, and adding final weight percent concentration is 75 to 90% heavy ethanol in this second liquid phase layer, forms the 3rd solid-phase layer and the 3rd liquid phase layer, gets the 3rd solid-phase layer, and with the 3rd solid matter drying.
The described compositions that protects the liver, wherein this Herba Artemisiae Scopariae is a Herba Artemisiae Scopariae, Herba Artemisiae Annuae, capillary wormwood, or its generic plant.
The described compositions that protects the liver, wherein this Fructus Gardeniae is a SHANZHIZI, Fructus Gardeniae grandiflorae, or its generic plant.
The described compositions that protects the liver, wherein this Radix Et Rhizoma Rhei is a Radix Et Rhizoma Rhei, water root Radix Et Rhizoma Rhei, or its generic plant.
The described compositions that protects the liver, wherein this step (a) more comprises the step of boiling with stirring.
The described compositions that protects the liver, wherein the cooling step of this step (a) is to be cooled to 10-80 ℃.
The described compositions that protects the liver, wherein this step (b) is to mix down in 10-80 ℃.
The described compositions that protects the liver, wherein the part by weight of this Herba Artemisiae Scopariae and Fructus Gardeniae and Radix Et Rhizoma Rhei is 4-8: 3-6: 0.5-2.5.
The described compositions that protects the liver, wherein the drying means of this step (d) is with lyophilization or spray drying or thermopnore drying.
Description of drawings
Fig. 1 is a schematic flow sheet of the present invention.
The specific embodiment
The present invention is relevant to a kind for the treatment of hepatitis composition and method of making the same, is to make with the following step: at first, after Herba Artemisiae Scopariae and the decoction of Fructus Gardeniae crushing and water-adding, the cooling that continues forms water extract; Wherein, this decoction step is repeatedly boiled and whipping step preferable comprising; And cooling step is preferably and is cooled to 10-80 ℃.Above-mentioned Herba Artemisiae Scopariae can be Herba Artemisiae Scopariae, Herba Artemisiae Annuae, capillary wormwood, or its generic plant; This Fructus Gardeniae can be SHANZHIZI, Fructus Gardeniae grandiflorae, or its generic plant.Afterwards this water collection liquid adding one is contained the alcohol-pickled liquid of Radix Et Rhizoma Rhei, preferable in 10-80 ℃ of following hybrid extraction.This Radix Et Rhizoma Rhei can be Radix Et Rhizoma Rhei, water root Radix Et Rhizoma Rhei, or its generic plant.Optionally add the alcohol-pickled liquid that contains Fructus Schisandrae Chinensis this moment.The part by weight of above-mentioned wherein this Herba Artemisiae Scopariae and Fructus Gardeniae and Radix Et Rhizoma Rhei is unrestricted, and the preferable Herba Artemisiae Scopariae that can be is 4-8: 3-6: 0.5-1.5 than Fructus Gardeniae than Radix Et Rhizoma Rhei, is more preferred from 4: 3: 1 or 4: 3: 2 or 4: 6: 1 or 8: 3: 2 equal proportions.
Can form first solid phase and first liquid phase after mixing,, then getting this first liquid phase layer and concentrate, making this first liquid phase layer formation concentrated solution this first solid phase and this first liquid phase separation; This concentrated solution is preferably the concentrated solution that solid holdup is the 1-30% percentage by weight.In this concentrated solution, add ethanol afterwards and make it produce precipitation, form second solid phase and second liquid phase.The final content of the ethanol that this step added is preferable greater than 30% percentage by weight, can optionally divide into two steps, one is the heavy ethanol of 71%-90% for adding ultimate density, make it produce precipitation, form second solid phase and second liquid phase, get this second solid-phase layer, and, prepare to pack this second solid matter drying.
Another step is the heavy ethanol of 30%-70% for adding ultimate density then, makes it produce precipitation, forms second solid phase and second liquid phase, gets this second solid-phase layer, and with this second solid matter drying, prepares to pack.And because the employed alcohol concentration of this step is lower, still some active substance stays in this second liquid phase layer, therefore it is 75 to 90% heavy ethanol that the second liquid phase layer continuation that will be left adds ultimate density, form the 3rd solid-phase layer and the 3rd liquid phase layer, get the 3rd solid-phase layer, and, prepare to pack with the 3rd solid matter drying.Above-mentioned drying means is not limit, and is preferably lyophilization or spray drying or thermopnore drying.Prepared finished product is drying and crushing further, pelletize and capsule charge.
For the clearer explanation of energy technology contents of the present invention, be described as follows especially exemplified by several preferred embodiment.Be noted that following is embodiment only, but not is limited to embodiment.For example this does not break away from basic framework person of the present invention, the interest field that all should be the present invention and advocated, and should be as the criterion with patent claim.
A. the preparation of extract
Embodiment 1
1. 6 kilograms of the SHANZHIZI of get it filled 8 kilograms of material Herba Artemisiae Scopariae, pulverizing add 144 kilograms of entry, place 250 liters decoction groove, mix and soak 13 hours.
2. stop heating after 1 hour with 80 ℃ of extractions, and with decoction liquor be cooled to 35 ℃ stand-by.
3. 2 kilograms of Radix Et Rhizoma Rheis and 95% ethanol of pulverizing is added in the above-mentioned decoction liquor for 48 kilograms, extracted 1 hour down in 35 ℃.
With above-mentioned decoction liquor with the 200mesh screen filtration, 168.89 kilograms of extractum liquid, recording solid holdup with moisture test apparatus is 1.01%.
5. above-mentioned extractum liquid is carried out concentrating under reduced pressure with vacuum concentration equipment, obtain 16.51 kilograms of concentrated solutions, the solid holdup that records concentrated solution with moisture test apparatus is 10.05%.
6. above-mentioned concentrated solution is placed stillpot, stir with mechanical agitator, and slowly add 15.58 kilograms of 95% ethanol, make final concentration of alcohol about 50%, stop to stir after reinforced the finishing, left standstill 1 hour.
7. with filter centrifugal the material in the above-mentioned stillpot is carried out centrifugal filtration, after filtration is finished, collect the filter cake on the filter bag, this filter cake with the freezer dryer drying, can be got about 65.26 g of lyophilization product, numbering ICH17.This product is carried out animal experiment, and test result is shown in table 1,3.
Embodiment 2
1. 6 kilograms of the SHANZHIZI of get it filled 8 kilograms of material Herba Artemisiae Scopariae, pulverizing add 144 kilograms of entry, place 250 liters decoction groove, mix and soak 13 hours.
2. stop heating after 1 hour with 80 ℃ of extractions, and with decoction liquor be cooled to 35 ℃ stand-by.
3. 2 kilograms of Radix Et Rhizoma Rheis pulverizing and 95% ethanol are added to for 48 kilograms and place above-mentioned decoction liquor, in 35 ℃ of extractions 1 hour down.
With above-mentioned decoction liquor with the 200mesh screen filtration, 168.89 kilograms of extractum liquid, recording solid holdup with moisture test apparatus is 1.01%.
5. above-mentioned extractum liquid is carried out concentrating under reduced pressure with vacuum concentration equipment, obtain 16.51 kilograms of concentrated solutions, the solid holdup that records concentrated solution with moisture test apparatus is 10.05%.
6. above-mentioned concentrated solution is placed stillpot, stir with mechanical agitator, and slowly add 62.3 kilograms of 95% ethanol, make final concentration of alcohol about 80%, stop to stir after reinforced the finishing, left standstill 1 hour.
8. with filter centrifugal the material in the above-mentioned stillpot is carried out centrifugal filtration, after filtration is finished, collect the filter cake on the filter bag, this filter cake with the freezer dryer drying, can be got about 182.26 g of lyophilization product, numbering ICH16.This product is carried out animal experiment, and test result is shown in table 1,3.
9. after above-mentioned filtrate of desiring to abandon being concentrated into finite concentration, place freezer dryer dry, can get about 1105.6 g of lyophilization product, numbering ICH19-1.This product is carried out animal experiment, and test result is shown in table 1,3.
Embodiment 3
1. 6 kilograms of the SHANZHIZI of get it filled 8 kilograms of material Herba Artemisiae Scopariae, pulverizing add 144 kilograms of entry, place 250 liters decoction groove, mix and soak 13 hours.
2. stop heating after 1 hour with 80 ℃ of extractions, and with decoction liquor be cooled to 35 ℃ stand-by.
3. 2 kilograms of Radix Et Rhizoma Rheis and 95% ethanol of pulverizing is added in the above-mentioned decoction liquor for 48 kilograms, extracted 1 hour down in 35 ℃.
With above-mentioned decoction liquor with the 200mesh screen filtration, 168.89 kilograms of extractum liquid, recording solid holdup with moisture test apparatus is 1.01%.
5. above-mentioned extractum liquid is carried out concentrating under reduced pressure with vacuum concentration equipment, obtain 16.51 kilograms of concentrated solutions, the solid holdup that records concentrated solution with moisture test apparatus is 10.05%.
6. above-mentioned concentrated solution is placed stillpot, stir with mechanical agitator, and slowly add 15.58 kilograms of 95% ethanol, make final concentration of alcohol about 50%, stop to stir after reinforced the finishing, left standstill 1 hour.
7. with filter centrifugal the material in the above-mentioned stillpot is carried out centrifugal filtration, after filtration is finished, collect filtrate, this filtrate is placed stillpot, stir with mechanical agitator again, and slowly add 46.73 kilograms of 95% ethanol, stop to stir after reinforced the finishing, left standstill 1 hour.
8. with filter centrifugal the material in the above-mentioned stillpot is carried out centrifugal filtration, collect the filter cake on the filter bag, this filter cake with the freezer dryer drying, can be got about 118.98 g of lyophilization product, numbering ICH20.This product is carried out animal experiment, and test result is shown in table 1,3.
9. after above-mentioned filtrate of desiring to abandon being concentrated into finite concentration, place freezer dryer dry, can get about 1102.7 g of lyophilization product, numbering ICH19.This product is carried out animal experiment, and test result is shown in table 1,3.
Embodiment 4-traditional water collection method
1. 6 kilograms of SHANZHIZI and the Radix Et Rhizoma Rhei of get it filled 8 kilograms of material Herba Artemisiae Scopariae, pulverizing add 144 kilograms of entry for 2 kilograms, place 250 liters decoction groove, mix and soak.
2. above-mentioned soak is stopped heating with 100 ℃ of decoctions after 1.5～2 hours, and decoction liquor is cooled off stand-by.
With above-mentioned decoction liquor with the 200mesh screen filtration, 112.2 kilograms of extractum liquid, recording solid holdup with moisture test apparatus is 1.03%.
4. above-mentioned extractum liquid is carried out concentrating under reduced pressure with vacuum concentration equipment, obtain 5.58 kilograms of concentrated solutions, the solid holdup that records concentrated solution with moisture test apparatus is 20.05%.
With above-mentioned concentrated solution with the freezer dryer drying, can get about 1118.79 g of lyophilization product, the numbering ICH.This product is carried out animal experiment, and test result is shown in table 1,3.
B. (in vivo) test in the animal body
By the prepared extract that goes out of aforementioned example, to through drug-induced and white mice that produce hepatic injury is handled, and observe the variation of GOT (Glutamyl Oxaloacetic Transaminase) in the mice serum and GPT (Glutamyl Pyrubic Transaminase).When liver cell sustains damage, can be discharged into the ferment in the liver in a large number in the blood, GOT and GPT value in the serum are risen.Therefore we relatively handle front and back at extract, and the reparation influence of extract for liver injury inferred in the variation of GOT and GPT in the mice serum; And by the situation of relatively inferring Mouse Liver swelling of liver weight.
(1) carbon tetrachloride brings out acute hepatitis
At random six of rat are divided into one group.Control group and oral throwing of poison group and distilled water during experiment, medicine (the ICH17 that the oral throwing of medicine group and different processing procedures are produced, ICH16, ICH19, ICH19-1, and ICH20, every group of dosage of throwing with identical medical material consumption, the various dose group is all first to be diluted to identical dose with Maltodextrin), oral throwing of reference drug group and silymarin (25mg/kg in 1%CMC), after 1 hour, each organizes lumbar injection CCl
4(1.5ml/kg inoliveoil, 20%), control group lumbar injection olive oil.CCl
4Injected back 24 hours, animal is with etherization, by the carotid artery blood sampling, separation of serum, serum left standstill 10 minutes in room temperature after, put into centrifuge (Backman, GS-6R, 3000rpm) centrifugal 10 minutes.Measure the activity of glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT).Result such as following table.
Table 1 animal experiment test result-CCl
4
| Dose (mg/kg) | GOT (U/L) | GPT (U/L) | |
| Normal | - | 129.83+7.03 | 49.37±2.06 |
| CCl 4 | - | 648.1±44.1 | 388.1±35.5 |
| CCl 4+Silymarin | 25 | 263.7±20.6 | 126.7±18.4 |
| CCl 4+ICH16 | 141.6 a | 236.3±27.5 *** | 171.2±42.9 |
| CCl 4+ICH17 | 50.7 a | 198.5±27.6 *** | 145.2±17.1 ** |
| CCl 4+ICH20 | 92.4 a | 184.9±22.3 *** | 164.4±21.3 * |
| CCl 4+ICH19 | 856.7 a | 384.3±27.2 | 412.8+64.7 |
| CCl 4+ICH19-1 | 858.9 a | 400.8±112.7 | 418.3±54.8 |
| CCl 4+ ICH (traditional water collection) | 1000 a | 426.5±56.2 ** | 143±26.6 ** |
(N=6,
*P＜0.05,
*P＜0.01,
* *P＜0.001 and CCl
4Group is compared, one wayANOVA followed by Scheffe ' s test)
A: because of the difference of concentrating degree thus the dosage of every group of test neither with, but every group of amount that gives is to come from identical medical material amount.
Ref：Recknagel?RO.Carbon?tetrachloride?hepatotoxicity.[Review][351refs]，Pharmacological?Reviews.19(2)：145-208，1967
(2) preparation of pathological tissue specimen
Carbon tetrachloride is brought out the laboratory animal that acute hepatitis test blood sampling finishes, liver is got in dissection, take off about 0.5 cubic centimeter hepatic tissue by every leaf again, after with 10% neutral formalin hepatic tissue being fixed for one to two week, again these hepatic tissues are oozed with dehydration that cured machine dewaters, paraffin embedding, be cut into the hepatic tissue section of about 4～5 μ m after the embedding with rotary microtome.Hepatic tissue section with Haematoxylin and Eosin dyeing, is observed the hepatic tissue section pathological change down in optical microscope.Result such as table 2.
Table 2 tissue slice Interpretation Report
| Slice number | ?Normal | ?CCl 4 | ??Silymarin | ??ICH16 | ??ICH20 | ??ICH17 |
| Organize observability (Tissue observations, liver) | ????T | ????T | ????T | ????T | ????T | ????T |
| The centrilobular region of liver steatosis (Fatty change, centrilobular) | ????- | ????2 | ????1 | ????1 | ????- | ????- |
| General sexual cell cavityization/swelling (Vacuolar degeneration/ Swollen cells, diffuse) | ????- | ????2 | ????2 | ????1 | ????1 | ????1 |
Symbol description:
T: tissue slice situation foot is for micro-assessment (Tissue present; Adequate formicroscopic evaluation)
Histologic lesion's order of severity assessment:
-: do not observe histologic lesion (No observation)
1: observe minimum (mineral) histologic lesion
2: observe slight (mild) histologic lesion
3: (moderate) histologic lesion that observes moderate
4: observe serious (severe) histologic lesion
(3) d-galactosamine brings out acute hepatitis
Per five of male white rat is divided into one group, every about 200 ± 20g, control group and the oral throwing of poison group and saline solution (0.9%NaCl) during experiment, medicine (the ICH17 that the oral throwing of medicine group and different processing procedures are produced, ICH16, ICH19, ICH19-1, and ICH20, every group of dosage of throwing with identical medical material consumption, the various dose group is all first to be diluted to identical dose with Maltodextrin), oral throwing of reference drug group and guanine (100mg/kg), after 0.5 hour, except that the control group, each organizes lumbar injection d-galactosamine (500mg/kg).D-galactosamine injects and distinctly offerd medicine once in back 4 hours, 8 hours again, and dosage is the same.D-galactosamine injected back 24 hours, animal is sacrificed blood sampling, and analyzing automatically with UV method collocation HITACHI is the activity that system (model 7050) is measured glutamateoxaloacetate transaminase (GOT) and glutamatepyruvate transaminase (GPT) in the serum.Result such as following table 3.
Table 3 d-galactosamine brings out acute hepatitis animal experiment test result
| Dose (mg/kg) | GOT (U/L) | GPT (U/L) | |
| Normal | - | 126.4±4.4 | 64.4±3.7 |
| d-gal | - | 1778.4±87.5 | 1035.6±95.2 |
| d-gal+Guanine | 300×3 | 1024.8±91.1 * | 602.4±61.7 |
| d-gal+ICH16 | 141.6 a×3 | 1498.0±168.6 * | 753.6±46.3 * |
| d-gal+ICH17 | 50.7 a×3 | 1406.4±156.9 * | 890.4±83.7 * |
| d-gal+ICH20 | 92.4 a×3 | 987.6±133.7 ** | 522.8±73.2 *** |
| d-gal+ICH19 | 856.7 a×3 | 2151.4±189.4 | 1304.9±124.5 |
| d-gal+ICH19-1 | 858.9 a×3 | 1926.0±169.4 | 1399.0±144.5 |
| D-gal+ICH (conventional process) | 1000 a×3 | 1462.0±337.5 * | 817.6±111.2 * |
(N＝5，
*p＜0.05，
**p＜0.01，
***p＜0.001)
A: because of the difference of concentrating degree thus the dosage of every group of test neither with, but every group of amount that gives is to come from identical medical material amount.
Ref：Keepler，D.，Lesch，R.，Reutler，W.and?Decher，K.Experimentalhepatitis?induced?by?D-galactosamine.Experiment?and?Molecular?Patholody9，279-290，1968
Can learn the prepared extract that goes out by The above results, for CCl by the present invention
4High GOT in the serum that is brought out and high GPT value have the reduction effect, especially compared to reference drug group (silymarin and guanine) and poison matched group (CCl
4With galactosamine) and traditional water collection group (ICH), the ICH16 that this processing procedure is prepared, ICH17, medicines such as ICH20 after the zoopery treatment, all have obviously to alleviate by CCl
4Or by the s-GOT that galactosamine caused, the effect that s-GPT rises.And, with reference drug group (silymarin) and poison matched group (CCl
4) relatively, use the prepared ICH16 of processing procedure of the present invention, ICH17, medicines such as ICH20 are to CCl
4The centrilobular region of liver steatosis that is caused (Fatty change, centrilobular) and general sexual cell cavityization/swelling (Vacuolardegeneration/Swollen cells, diffuse) situation all have the effect of alleviating.Meaning is the prepared medicine that goes out of processing procedure of the present invention, the effect that has protection or repair for injured liver.
Via the product of manufacturing method thereof gained of the present invention, can effectively the active ingredient substance abstraction purification be concentrated, table 4 can illustrate that processing procedure of the present invention has the spissated value of high magnification.
The concentration rate dependency of table 4 processing procedure product of the present invention and conventional process product
| Medical material use amount (kg) a | Ultimate output (g) | The concentration rate ratio | Animal experiment is thrown and amount (mg/kg) | Animal experiment is thrown and amount dosage ratio | |
| Conventional process | 16 | 1119 | ????1 | ????1000 | ????1 |
| (ICH17) | 16 | 65.26 | ????17.1 | ????50.7 | ????0.05 |
| (ICH20) | 16 | 118.98 | ????9.4 | ????92.4 | ????0.09 |
| (ICH16) | 16 | 182.26 | ????6.1 | ????141.6 | ????0.14 |
Contain 2 kilograms of 8 kilograms of Herba Artemisiae Scopariae, 6 kilograms of the SHANZHIZI of pulverizing and Radix Et Rhizoma Rheis in the a:16 kilogram medical material
As shown in Table 4, when using the medical material (16 kilograms) of identical weight, conventional process can be produced the end product of 1119 grams, processing procedure of the present invention is then because through the spissated step of purification, so when using identical weight medical material, can obtain 65.26g respectively according to different procedure for producing, 118.98g and the end product of 182.26g, when data are compared with conventional process as can be known thus, the medicine multiplying power that processing procedure of the present invention can get the conventional process preparation further promotes 17.1～6.1 times, therefore, when the medicine that utilizes this processing procedure patent to be produced carries out animal experiment, reason owing to concentration rate, can and measure 0.05～0.14 times that reduce to the conventional process taking dose with the animal experiment throwing, can obtain being better than the effect of traditional taking dose even reference dose.Therefore, show that processing procedure of the present invention can come together and complete effective ingredient, and effectively reduce using dosage, compared to conventional process, the progressive that real tool is suitable.
In addition, the inventor finds that through further investigation the active substance in the Radix Et Rhizoma Rhei is subject to heat damage, therefore, especially with it with alcohol-pickled, with this active substance of stripping, and do not obtain this active substance in the decocting mode of boiling.And consider the temperature sensitivity of active substance, the spy separates Radix Et Rhizoma Rhei and other medical material, treats to add after other medical material decocts cooling again, reduces the destruction of high temperature decoction process to active substance.Processing procedure of the present invention also utilizes the skill of partial purification, unnecessary composition appropriateness is removed, to obtain highly enriched active ingredient composition.By aforementioned preparation of the present invention as can be known, break through the traditional decoction method, not only can extract active substance in a large number, and the technology of utilizing separation and purification is with the complete preservation of active substance.Therefore, the real tool novelty of processing procedure of the present invention.
In addition, the present invention is not with deleterious organic solvent extraction, and is only with the active substance in pharmaceutical grade ethanol and the water extraction plant, harmless.And have the knack of this technical field person and all know, only use ethanol to be difficult to reach good effect of extracting; The right inventor is through further investigation and repeatedly experiment, found to access the maximum active substance must alcohol concentration accurate scope, and find that further its effective ingredient ratio is quite high, proves that through zoopery its effect is fairly good really with twice obtained product of alcohol precipitation.The concentrate solid holdup of also finding simultaneously concentration step is quite important for improving the active substance ratio, the technology that this had not also been disclosed in the prior art.
Claims (29)
1, a kind of preparation of compositions method that protects the liver is characterized in that: comprise the following steps:
(a) with Herba Artemisiae Scopariae and Fructus Gardeniae crushing and water-adding and heating;
(b) with this water collection liquid, add an alcohol-pickled liquid that contains Radix Et Rhizoma Rhei and mix, form one first solid phase and one first liquid phase;
(c) get this first liquid phase layer and concentrating, make this first liquid phase layer form concentrated solution; And
(d) in this concentrated solution, add ethanol and make it produce precipitation, form second solid phase and second liquid phase, get this second solid-phase layer, and with this second solid matter drying.
2, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: it more is contained in and adds the alcohol-pickled liquid that contains Fructus Schisandrae Chinensis in the step (b).
3, according to the described preparation of compositions method that protects the liver of claim 1, wherein the concentration step of this step (c) is to be the concentrated solution of 1-30% percentage by weight with this water collection liquid simmer down to solid holdup.
4, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein the ethanol final weight percent concentration of this step (d) is that 71%-90% is heavy.
5, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein the ethanol final weight percent concentration of this step (d) is that 30%-70% is heavy.
6, according to the described preparation of compositions method that protects the liver of claim 5, it is characterized in that: it more is contained in, and adding ethanol to ethanol final weight percent concentration reaches 75% to 90% weight in this second liquid phase layer, to form the 3rd solid-phase layer and the 3rd liquid phase layer, get the 3rd solid-phase layer, and with the 3rd solid matter drying.
7, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein this Herba Artemisiae Scopariae is a Herba Artemisiae Scopariae, Herba Artemisiae Annuae, capillary wormwood, or its generic plant.
8, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein this Fructus Gardeniae is a SHANZHIZI, Fructus Gardeniae grandiflorae, or its generic plant.
9, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein this Radix Et Rhizoma Rhei is a Radix Et Rhizoma Rhei, water root Radix Et Rhizoma Rhei, or its generic plant.
10, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein this step (a) more comprises the step of boiling with stirring.
11, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein the cooling step of this step (a) is to be cooled to 10-80 ℃.
12, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein this step (b) is to mix down in 10-80 ℃.
13, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein the drying means of this step (d) is with lyophilization or spray drying or thermopnore drying.
14, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: wherein the part by weight of this Herba Artemisiae Scopariae and Fructus Gardeniae and Radix Et Rhizoma Rhei is 4-8: 3-6: 0.5-2.5.
15, according to the described preparation of compositions method that protects the liver of claim 1, it is characterized in that: it more comprises the end product drying and crushing, pelletize and capsule charge.
16. one kind protects the liver compositions, it is characterized in that: it is to make in the following manner:
(a) with Herba Artemisiae Scopariae and Fructus Gardeniae crushing and water-adding and heating;
(b) with this water collection liquid, add an alcohol-pickled liquid that contains Radix Et Rhizoma Rhei and mix, form first solid phase and first liquid phase;
(c) get this first liquid phase layer and concentrating, make this first liquid phase layer form concentrated solution; And
(d) in this concentrated solution, add ethanol and make it produce precipitation, form second solid phase and second liquid phase, get this second solid-phase layer, and with this second solid matter drying.
17, the compositions that protects the liver according to claim 16 is characterized in that: it more is contained in and adds the alcohol-pickled liquid that contains Fructus Schisandrae Chinensis in the step (b).
18, the compositions that protects the liver according to claim 16 is characterized in that: wherein the concentration step of this step (c) is to be the concentrated solution of 1-30% percentage by weight with this water collection liquid simmer down to solid holdup.
19, the compositions that protects the liver according to claim 16 is characterized in that: wherein the ethanol final weight percent concentration of this step (d) is that 71%-90% is heavy.
20, the compositions that protects the liver according to claim 16 is characterized in that: wherein the ethanol final weight percent concentration of this step (d) is that 30%-70% is heavy.
21, the compositions that protects the liver according to claim 20, it is characterized in that: it more is contained in, and adding final weight percent concentration is 75 to 90% heavy ethanol in this second liquid phase layer, form the 3rd solid-phase layer and the 3rd liquid phase layer, get the 3rd solid-phase layer, and with the 3rd solid matter drying.
22, the compositions that protects the liver according to claim 16 is characterized in that: wherein this Herba Artemisiae Scopariae is a Herba Artemisiae Scopariae, Herba Artemisiae Annuae, capillary wormwood, or its generic plant.
23, the compositions that protects the liver according to claim 16 is characterized in that: wherein this Fructus Gardeniae is a SHANZHIZI, Fructus Gardeniae grandiflorae, or its generic plant.
24, the compositions that protects the liver according to claim 16 is characterized in that: wherein this Radix Et Rhizoma Rhei is a Radix Et Rhizoma Rhei, water root Radix Et Rhizoma Rhei, or its generic plant.
25, the compositions that protects the liver according to claim 16, wherein this step (a) more comprises the step of boiling with stirring.
26, the compositions that protects the liver according to claim 16 is characterized in that: wherein the cooling step of this step (a) is to be cooled to 10-80 ℃.
27, the compositions that protects the liver according to claim 16 is characterized in that: wherein this step (b) is to mix down in 10-80 ℃.
28, the compositions that protects the liver according to claim 16 is characterized in that: wherein the part by weight of this Herba Artemisiae Scopariae and Fructus Gardeniae and Radix Et Rhizoma Rhei is 4-8: 3-6: 0.5-2.5.
29, the compositions that protects the liver according to claim 16 is characterized in that: wherein the drying means of this step (d) is with lyophilization or spray drying or thermopnore drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021608997A CN100363027C (en) | 2002-12-31 | 2002-12-31 | Liver-care composition and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021608997A CN100363027C (en) | 2002-12-31 | 2002-12-31 | Liver-care composition and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513486A true CN1513486A (en) | 2004-07-21 |
| CN100363027C CN100363027C (en) | 2008-01-23 |
Family
ID=34238036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021608997A Expired - Lifetime CN100363027C (en) | 2002-12-31 | 2002-12-31 | Liver-care composition and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100363027C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940642A (en) * | 2010-10-08 | 2011-01-12 | 华东理工大学 | Chinese medicinal composition and application thereof |
| CN101002849B (en) * | 2007-01-30 | 2011-01-26 | 中国人民解放军第三○二医院 | Traditional Chinese medicine extractive or tablet for treating hepatitis, and its preparing method |
-
2002
- 2002-12-31 CN CNB021608997A patent/CN100363027C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002849B (en) * | 2007-01-30 | 2011-01-26 | 中国人民解放军第三○二医院 | Traditional Chinese medicine extractive or tablet for treating hepatitis, and its preparing method |
| CN101940642A (en) * | 2010-10-08 | 2011-01-12 | 华东理工大学 | Chinese medicinal composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100363027C (en) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1839996A (en) | Chinese traditional medicine compound preparation for treating chronic hepatiosis and preparation method thereof | |
| CN1513486A (en) | Liver-care composition and its prepn. method | |
| CN1899415A (en) | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method | |
| TWI334782B (en) | A pharmaceutical mixture for hepatitis treatment and its preparation method | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1290520C (en) | Method for preparing hepatitis treating medicine and the product produced thereby | |
| CN1742926A (en) | Zuoci preparation for deaf and new preparing method thereof | |
| CN1899388A (en) | Shuangdan soft capsule and its preparing method | |
| CN1748741A (en) | Little leaf deervetch herb acne removing preparation and new preparing method | |
| CN1686414A (en) | Wound dispelling swell dispersing tincture and its preparation method | |
| CN1824109A (en) | Liaoyuanqili medicinal preparation and its new preparation method | |
| CN1067256C (en) | Concentrated chinese medicine preparation and its preparation process | |
| CN1310635C (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1286480C (en) | Oral disintegrants of composite salvia miltiorrhiza and their preparation | |
| CN1283246C (en) | Complex rheum officinale-radix scutellariae extract injecta for treating acute pancreatitis and preparing method thereof | |
| CN1224397C (en) | Medicine for treating chronic nephritis and production process thereof | |
| CN1490001A (en) | Hepadestal drops and preparation thereof | |
| CN1281252C (en) | Medicinal composition for treating urinary lithiasis and its preparing method | |
| CN1225277C (en) | Chinese medicinal composition for treating epilepsy disease and its preparation method | |
| CN1768775A (en) | Prescription containing sweet clover component and its formulation | |
| CN1824111A (en) | Cold dissipating network vessel quickening medicinal preparation and its new preparation method | |
| CN1824013A (en) | Four material leenurus preparation and its new preparing method | |
| CN1795901A (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN1590396A (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20080123 |